ArticleThe British journal of ophthalmology1995
Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease.
Article in The British journal of ophthalmology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 72 citations in OpenAlex.
- Early and Pronounced PVR Reaction After Revitrectomy With Allogeneic Platelet Concentrate in Persistent Macular Hole.Case reports in ophthalmological medicine · 2026Article
- Recurrent rhegmatogenous retinal detachment after primary vitrectomy by surgeons in training - incidence and predictive factors.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Retinal redetachment after silicone oil removal: a risk factor analysis.BMC ophthalmology · 2024Observational
- Epiretinal Amniotic Membrane in Complicated Retinal Detachment: a Clinical and In Vitro Safety Assessment.Ophthalmology and therapy · 2023Article
- [Reasons and risk factors for recurrent retinal detachment after removal of silicon oil in various vitreoretinal diseases].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022Article
- Systemic Curcumin-Human Serum Albumin in Proliferative Vitreoretinal Retinopathy: A Pilot Study.Cureus · 2021Article
- [Proliferative vitreoretinopathy process-To heal or not to heal].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- A sustained dual drug delivery system for proliferative vitreoretinopathy.Drug delivery · 2020Article
- Comment on: Sandwich technique using a combination of perfluoropropane and silicone oil for inferior retinal detachment.Indian journal of ophthalmology · 2019Article
- Scleral buckle surgery in Ghana: a decade comparison of the anatomic and visual outcome.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies.Drug delivery · 2018Article
- A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.Drug delivery · 2017Article
- Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.Eye (London, England) · 2017Article
- Correlation between miR-148 Expression in Vitreous and Severity of Rhegmatogenous Retinal Detachment.BioMed research international · 2017Article
- A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.Investigative ophthalmology & visual science · 2015Article
- Deferred laser photocoagulation of relaxing retinotomies under silicone oil tamponade to reduce recurrent macular detachment in severe proliferative vitreoretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2014Article
- Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.Acta biomaterialia · 2014Article
- Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2013Article
- Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.Investigative ophthalmology & visual science · 2013Article
- The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy.PloS one · 2013Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aimed to evaluate both the mean time intervals between retinal disease and the development of proliferative vitreoretinopathy (PVR) and the time intervals at which recurrent PVR develops following various kinds of vitreoretinal disease and surgery.
methodsOne hundred and thirty six consecutive cases of PVR that were seen and operated on between 1991 and 1994 were evaluated retrospectively. Intervals between onset of disease and PVR or recurrent PVR were noted. Conditions leading to PVR, surgical procedures, and the final anatomical and functional results were evaluated.
resultsBefore PVR was noted for the first time, an average of 1.06 vitreoretinal surgical procedures were performed (range 0 to 3). A mean of 1.99 surgeries were performed to control PVR or to reach an end stage where further surgery would have been unreasonable (range 0 to 5). The average (median) time interval between the onset of the retinal disease and PVR was 2.0 months (range 0.5 to 45 months). The median time intervals between surgery and recurrence for the second, third, or fourth times was also 2.0 months (range 0.5 to 34 months).
conclusionsPVR starts earliest at 2 weeks after an event and subsequently quietens down within a maximum of 45 months after treatment (median 2 months). PVR may recur more than once but the time course of the disease is likely to be the same for each recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.